全文获取类型
收费全文 | 32491篇 |
免费 | 1889篇 |
国内免费 | 156篇 |
专业分类
耳鼻咽喉 | 321篇 |
儿科学 | 785篇 |
妇产科学 | 813篇 |
基础医学 | 4792篇 |
口腔科学 | 1884篇 |
临床医学 | 2727篇 |
内科学 | 7275篇 |
皮肤病学 | 982篇 |
神经病学 | 2814篇 |
特种医学 | 537篇 |
外科学 | 2611篇 |
综合类 | 128篇 |
一般理论 | 21篇 |
预防医学 | 3663篇 |
眼科学 | 524篇 |
药学 | 2566篇 |
中国医学 | 192篇 |
肿瘤学 | 1901篇 |
出版年
2024年 | 42篇 |
2023年 | 386篇 |
2022年 | 876篇 |
2021年 | 1541篇 |
2020年 | 869篇 |
2019年 | 1254篇 |
2018年 | 1519篇 |
2017年 | 1014篇 |
2016年 | 968篇 |
2015年 | 1202篇 |
2014年 | 1575篇 |
2013年 | 1944篇 |
2012年 | 2962篇 |
2011年 | 3126篇 |
2010年 | 1563篇 |
2009年 | 1301篇 |
2008年 | 2153篇 |
2007年 | 2098篇 |
2006年 | 1821篇 |
2005年 | 1595篇 |
2004年 | 1385篇 |
2003年 | 1164篇 |
2002年 | 1012篇 |
2001年 | 128篇 |
2000年 | 82篇 |
1999年 | 106篇 |
1998年 | 136篇 |
1997年 | 132篇 |
1996年 | 84篇 |
1995年 | 67篇 |
1994年 | 66篇 |
1993年 | 52篇 |
1992年 | 51篇 |
1991年 | 32篇 |
1990年 | 28篇 |
1989年 | 22篇 |
1988年 | 19篇 |
1987年 | 22篇 |
1986年 | 16篇 |
1985年 | 12篇 |
1984年 | 13篇 |
1983年 | 13篇 |
1982年 | 15篇 |
1981年 | 9篇 |
1980年 | 13篇 |
1978年 | 6篇 |
1976年 | 6篇 |
1975年 | 7篇 |
1973年 | 5篇 |
1972年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
111.
Eva Tabernero Huguet Borja Ortiz de Urbina Antia Beatriz González Quero Elena Garay Llorente Joseba Andia Iturrate Silvia Pérez Fernández Ana Gómez Larrauri Milagros Iriberri Pascual 《Archivos de bronconeumologia》2021,57(5):345-350
IntroductionNECPAL is a tool for identification of patients with advanced chronic disease in need of palliative care. The main objective of the study is to know the prevalence of patients with palliative needs in an acute respiratory ward in a Spanish tertiary hospital using NECPAL. A second objective of the study is to know the annual mortality rate of these patients.Materials and methodsCross sectional study and prospective monitoring of a cohort identified as palliative patients with the NECPAL tool for 12 months. Patient identification was performed in patients admitted to the respiratory ward of our hospital for longer than 3 days. We have assessed the annual vital status (deceased or not deceased) of patients and have recorded demographics, clinical and functional data, as well as the use of healthcare resources.ResultsWe monitored a cohort of 363 patients. Of them, 87 patients (24.3%) (IC 95% 19–30) were identified as NECPAL positive. 60% of patients (n = 64) died within 12 months of their admission. There was no significant difference in the mortality ratio of oncologic versus non oncologic patients. In a multivariable analysis, mortality was associated with demand by patients or relatives for palliative care and with the presence of specific disease progression markers or indicators.Conclusionsprevalence of patients with palliative needs in acute respiratory wards is high (one out of four patients). 60% of the patients identified as NECPAL positive in our cohort died in the first 12 months. Training of healthcare professionals as well as availability of appropriate resources are indispensable factors to improve care of this population. 相似文献
112.
Carlos Solano Lourdes Vázquez Estela Giménez Rafael de la Cámara Eliseo Albert Montserrat Rovira Ildefonso Espigado Carmen M. Calvo Javier López-Jiménez María Suárez-Lledó Anabella Chinea Albert Esquirol Ariadna Pérez Aránzazu Bermúdez Raquel Saldaña Inmaculada Heras Ana J. González-Huerta Tamara Torrado Guiomar Bautista Montserrat Batlle Santiago Jiménez Carlos Vallejo Pere Barba María Á. Cuesta José L. Piñana David Navarro 《American journal of transplantation》2021,21(1):258-271
The net impact of cytomegalovirus (CMV) DNAemia on overall mortality (OM) and nonrelapse mortality (NRM) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a matter of debate. This was a retrospective, multicenter, noninterventional study finally including 749 patients. CMV DNA monitoring was conducted by real-time polymerase chain reaction (PCR) assays. Clinical outcomes of interest were OM and NRM through day 365 after allo-HSCT. The cumulative incidence of CMV DNAemia in this cohort was 52.6%. A total of 306 out of 382 patients with CMV DNAemia received preemptive antiviral therapy (PET). PET use for CMV DNAemia, but not the occurrence of CMV DNAemia, taken as a qualitative variable, was associated with increased OM and NRM in univariate but not in adjusted models. A subcohort analysis including patients monitored by the COBAS Ampliprep/COBAS Taqman CMV Test showed that OM and NRM were comparable in patients in whom either low or high plasma CMV DNA threshold (<500 vs ≥500 IU/mL) was used for PET initiation. In conclusion, CMV DNAemia was not associated with increased OM and NRM in allo-HSCT recipients. The potential impact of PET use on mortality was not proven but merits further research. 相似文献
113.
Aránzazu Caballero-Marcos Magdalena Salcedo Roberto Alonso-Fernández Manuel Rodríguez-Perálvarez María Olmedo Javier Graus Morales Valentín Cuervas-Mons Alba Cachero Carmelo Loinaz-Segurola Mercedes Iñarrairaegui Lluís Castells Sonia Pascual Carmen Vinaixa-Aunés Rocío González-Grande Alejandra Otero Santiago Tomé Javier Tejedor-Tejada José María Álamo-Martínez Luisa González-Diéguez Flor Nogueras-Lopez Gerardo Blanco-Fernández Gema Muñoz-Bartolo Francisco Javier Bustamante Emilio Fábrega Mario Romero-Cristóbal Rosa Martin-Mateos Julia Del Rio-Izquierdo Ana Arias-Milla Laura Calatayud Alberto A. Marcacuzco-Quinto Víctor Fernández-Alonso Concepción Gómez-Gavara Jordi Colmenero Patricia Muñoz José A. Pons the Spanish Society of Liver Transplantation 《American journal of transplantation》2021,21(8):2876-2884
The protective capacity and duration of humoral immunity after SARS-CoV-2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case–control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p < .001) and at 6 months (63.4% vs. 90.1%, p < .001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p = .001) and 6 months (p < .001) after COVID-19. In transplant patients, female gender (OR = 13.49, 95% CI: 2.17–83.8), a longer interval since transplantation (OR = 1.19, 95% CI: 1.03–1.36), and therapy with renin–angiotensin–aldosterone system inhibitors (OR = 7.11, 95% CI: 1.47–34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS-CoV-2 antibodies and more pronounced antibody levels decline. 相似文献
114.
Escalante-Mañe Ana M. Hernández-Nuñez Emanuel Méndez-Novelo Roger I. Giácoman-Vallejos Germán González-Sánchez Avel A. Quintanilla-Mena Mercedes A. Romellón-Orozco Mariana E. Puch-Hau Carlos 《Bulletin of environmental contamination and toxicology》2022,108(3):526-531
Bulletin of Environmental Contamination and Toxicology - We report the chemical characterisation and toxic effects of municipal solid waste landfill leachates on the embryonic development of Danio... 相似文献
115.
116.
Fabrício Silveira Ana Luísa Martins Paulo Gadelha Rmulo Paes-Sousa 《Bulletin of the World Health Organization》2021,99(3):228
The extended scope and complexity of the United Nations 2030 agenda entail important challenges for the operationalization of the health-related sustainable development goal (SDG) indicators. Divergences in concepts, agendas and implementation strategies among institutions have fostered the parallel development of alternative and concurrent indicators. We aim to determine the convergences and divergences between five key institutions: the Global Burden of Disease Study (GBD), the Pan American Health Organization, the Sustainable Development Solutions Network, the World Bank and the World Health Organization (WHO). Of the 104 health-related indicators listed by these five institutions, 60 are consistent with official Inter-agency and Expert Group SDG indicators. Our analysis considers the indicators included, and the themes these indicators cover, in each institution list and each institution online platform. We quantified convergence in indicators between the institutions themselves, but also between the institutions and the official Inter-agency and Expert Group. Our results indicate important divergences; only 22 of the 60 indicators are included in the lists of all five institutions. The level of adoption of the official metrics varies from 40.5% (15/(47−10)) for the GBD to 86.2% (25/(29−0)) for the World Bank. WHO, the official curator of the Inter-agency and Expert Group SDG indicators, is only convergent with the official metrics by 72.1% (31/(45−2)). Our analysis, and the resulting awareness of the differences, potentialities and limitations of indicators and platforms, provides important contributions to enable the achievement of the health-related SDGs and deliver the promise of the 2030 agenda. 相似文献
117.
118.
Louise B. Russell Sun-Young Kim Cristiana Toscano Ben Cosgriff Ruth Minamisava Ana Lucia Andrade Colin Sanderson Anushua Sinha 《Vaccine》2021,39(1):158-166
BackgroundThis paper compares cost-effectiveness results from two models of maternal immunization to prevent pertussis in infants in Brazil, one static, one dynamic, to explore when static models are adequate for public health decisions and when the extra effort required by dynamic models is worthwhile.MethodsWe defined two scenarios to explore key differences between static and dynamic models, herd immunity and time horizon. Scenario 1 evaluates the incremental cost/DALY of maternal acellular pertussis (aP) immunization as routine infant vaccination coverage ranges from low/moderate up to, and above, the threshold at which herd immunity begins to eliminate pertussis. Scenario 2 compares cost-effectiveness estimates over the models’ different time horizons. Maternal vaccine prices of $9.55/dose (base case) and $1/dose were evaluated.ResultsThe dynamic model shows that maternal immunization could be cost-saving as well as life-saving at low levels of infant vaccination coverage. When infant coverage reaches the threshold range (90–95%), it is expensive: the dynamic model estimates that maternal immunization costs $2 million/DALY at infant coverage > 95% and maternal vaccine price of $9.55/dose; at $1/dose, cost/DALY is $200,000. By contrast, the static model estimates costs/DALY only modestly higher at high than at low infant coverage. When the models’ estimates over their different time horizons are compared at infant coverage < 90–95%, their projections fall in the same range.ConclusionsStatic models may serve to explore an intervention’s cost-effectiveness against infectious disease: the direction and principal drivers of change were the same in both models. When, however, an intervention too small to have significant herd immunity effects itself, such as maternal aP immunization, takes place against a background of vaccination in the rest of the population, a dynamic model is crucial to accurate estimates of cost-effectiveness. This finding is particularly important in the context of widely varying routine infant vaccination rates globally.Clinical Trial registryClinical Trial registry name and registration number: Not applicable. 相似文献
119.
120.
Dayana A. Delgado Meytal Chernoff Lei Huang Lin Tong Lin Chen Farzana Jasmine Justin Shinkle Shelley A. Cole Karin Haack Jack Kent Jason Umans Lyle G. Best Heather Nelson Donald Vander Griend Joseph Graziano Muhammad G. Kibriya Ana Navas-Acien Margaret R. Karagas Habibul Ahsan Brandon L. Pierce 《Environmental health perspectives》2021,129(5)